Relevance Between Programmed Death Ligand 1 and Radiologic Invasiveness in Pathologic Stage I Lung Adenocarcinoma

Gouji Toyokawa, Kazuki Takada, Tatsuro Okamoto, Satoshi Kawanami, Yuka Kozuma, Taichi Matsubara, Naoki Haratake, Shinkichi Takamori, Takaki Akamine, Masakazu Katsura, Yuichi Yamada, Fumihiro Shoji, Shingo Baba, Takeshi Kamitani, Yoshinao Oda, Hiroshi Honda, Yoshihiko Maehara

研究成果: ジャーナルへの寄稿記事

12 引用 (Scopus)

抄録

Background Programmed death ligand 1 (PD-L1) was reported to predict the response of immunotherapy; however, the association between PD-L1 expression and radiologic and pathologic features has yet to be elucidated. Methods In all, 292 patients with resected pathologic stage I adenocarcinoma were analyzed for PD-L1 expression by immunohistochemistry and evaluated to determine the association between PD-L1 expression and the radiologic/pathologic invasiveness. Specifically, the radiologic invasiveness and noninvasiveness were determined based on the consolidation/tumor ratio, with a cutoff value of 0.25 by thin-section computed tomography. Results Among 292 patients, 47 (16.1%) were positive for PD-L1 expression; the remaining 245 patients (83.9%) were negative for PD-L1 expression. Fisher's exact test demonstrated that PD-L1 expression was significantly associated with a higher consolidation/tumor ratio (p = 0.029) and higher maximum standardized uptake value (p = 0.004). The mean values of consolidation/tumor ratio and maximum standardized uptake in patients with and without PD-L1 expression were 0.845 ± 0.052 and 7.241 ± 0.795, and 0.607 ± 0.023 and 3.60 ± 0.364, respectively (p < 0.001 and p < 0.001, respectively). Among 47 adenocarcinomas harboring PD-L1 expression, the frequencies of PD-L1 expression for consolidation/tumor ratios of 0, 0.1 to 0.25, 0.26 to 0.5, and 0.51 or more were 6.4%, 2.1%, 4.3%, and 87.2%, respectively (p = 0.007). Pathologically, PD-L1 was identified exclusively only in more invasive subtypes, not in less invasive ones, such as atypical adenomatous hyperplasia, adenocarcinoma in situ, minimally invasive adenocarcinoma, and lepidic predominant ones (p < 0.001). Conclusions Expression of PD-L1 was significantly associated with radiologic/pathologic invasive adenocarcinomas. This study provides the first evidence of the radiologic and pathologic invasiveness in resected pathologic stage I adenocarcinoma with PD-L1 expression.

元の言語英語
ページ(範囲)1750-1757
ページ数8
ジャーナルAnnals of Thoracic Surgery
103
発行部数6
DOI
出版物ステータス出版済み - 6 1 2017

Fingerprint

Ligands
Adenocarcinoma
Adenocarcinoma of lung
Neoplasms
Immunotherapy
Hyperplasia
Immunohistochemistry
Tomography

All Science Journal Classification (ASJC) codes

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine

これを引用

Toyokawa, G., Takada, K., Okamoto, T., Kawanami, S., Kozuma, Y., Matsubara, T., ... Maehara, Y. (2017). Relevance Between Programmed Death Ligand 1 and Radiologic Invasiveness in Pathologic Stage I Lung Adenocarcinoma. Annals of Thoracic Surgery, 103(6), 1750-1757. https://doi.org/10.1016/j.athoracsur.2016.12.025

Relevance Between Programmed Death Ligand 1 and Radiologic Invasiveness in Pathologic Stage I Lung Adenocarcinoma. / Toyokawa, Gouji; Takada, Kazuki; Okamoto, Tatsuro; Kawanami, Satoshi; Kozuma, Yuka; Matsubara, Taichi; Haratake, Naoki; Takamori, Shinkichi; Akamine, Takaki; Katsura, Masakazu; Yamada, Yuichi; Shoji, Fumihiro; Baba, Shingo; Kamitani, Takeshi; Oda, Yoshinao; Honda, Hiroshi; Maehara, Yoshihiko.

:: Annals of Thoracic Surgery, 巻 103, 番号 6, 01.06.2017, p. 1750-1757.

研究成果: ジャーナルへの寄稿記事

Toyokawa, G, Takada, K, Okamoto, T, Kawanami, S, Kozuma, Y, Matsubara, T, Haratake, N, Takamori, S, Akamine, T, Katsura, M, Yamada, Y, Shoji, F, Baba, S, Kamitani, T, Oda, Y, Honda, H & Maehara, Y 2017, 'Relevance Between Programmed Death Ligand 1 and Radiologic Invasiveness in Pathologic Stage I Lung Adenocarcinoma', Annals of Thoracic Surgery, 巻. 103, 番号 6, pp. 1750-1757. https://doi.org/10.1016/j.athoracsur.2016.12.025
Toyokawa, Gouji ; Takada, Kazuki ; Okamoto, Tatsuro ; Kawanami, Satoshi ; Kozuma, Yuka ; Matsubara, Taichi ; Haratake, Naoki ; Takamori, Shinkichi ; Akamine, Takaki ; Katsura, Masakazu ; Yamada, Yuichi ; Shoji, Fumihiro ; Baba, Shingo ; Kamitani, Takeshi ; Oda, Yoshinao ; Honda, Hiroshi ; Maehara, Yoshihiko. / Relevance Between Programmed Death Ligand 1 and Radiologic Invasiveness in Pathologic Stage I Lung Adenocarcinoma. :: Annals of Thoracic Surgery. 2017 ; 巻 103, 番号 6. pp. 1750-1757.
@article{1ae37a063e3c4f46921204c26edda664,
title = "Relevance Between Programmed Death Ligand 1 and Radiologic Invasiveness in Pathologic Stage I Lung Adenocarcinoma",
abstract = "Background Programmed death ligand 1 (PD-L1) was reported to predict the response of immunotherapy; however, the association between PD-L1 expression and radiologic and pathologic features has yet to be elucidated. Methods In all, 292 patients with resected pathologic stage I adenocarcinoma were analyzed for PD-L1 expression by immunohistochemistry and evaluated to determine the association between PD-L1 expression and the radiologic/pathologic invasiveness. Specifically, the radiologic invasiveness and noninvasiveness were determined based on the consolidation/tumor ratio, with a cutoff value of 0.25 by thin-section computed tomography. Results Among 292 patients, 47 (16.1{\%}) were positive for PD-L1 expression; the remaining 245 patients (83.9{\%}) were negative for PD-L1 expression. Fisher's exact test demonstrated that PD-L1 expression was significantly associated with a higher consolidation/tumor ratio (p = 0.029) and higher maximum standardized uptake value (p = 0.004). The mean values of consolidation/tumor ratio and maximum standardized uptake in patients with and without PD-L1 expression were 0.845 ± 0.052 and 7.241 ± 0.795, and 0.607 ± 0.023 and 3.60 ± 0.364, respectively (p < 0.001 and p < 0.001, respectively). Among 47 adenocarcinomas harboring PD-L1 expression, the frequencies of PD-L1 expression for consolidation/tumor ratios of 0, 0.1 to 0.25, 0.26 to 0.5, and 0.51 or more were 6.4{\%}, 2.1{\%}, 4.3{\%}, and 87.2{\%}, respectively (p = 0.007). Pathologically, PD-L1 was identified exclusively only in more invasive subtypes, not in less invasive ones, such as atypical adenomatous hyperplasia, adenocarcinoma in situ, minimally invasive adenocarcinoma, and lepidic predominant ones (p < 0.001). Conclusions Expression of PD-L1 was significantly associated with radiologic/pathologic invasive adenocarcinomas. This study provides the first evidence of the radiologic and pathologic invasiveness in resected pathologic stage I adenocarcinoma with PD-L1 expression.",
author = "Gouji Toyokawa and Kazuki Takada and Tatsuro Okamoto and Satoshi Kawanami and Yuka Kozuma and Taichi Matsubara and Naoki Haratake and Shinkichi Takamori and Takaki Akamine and Masakazu Katsura and Yuichi Yamada and Fumihiro Shoji and Shingo Baba and Takeshi Kamitani and Yoshinao Oda and Hiroshi Honda and Yoshihiko Maehara",
year = "2017",
month = "6",
day = "1",
doi = "10.1016/j.athoracsur.2016.12.025",
language = "English",
volume = "103",
pages = "1750--1757",
journal = "Annals of Thoracic Surgery",
issn = "0003-4975",
publisher = "Elsevier USA",
number = "6",

}

TY - JOUR

T1 - Relevance Between Programmed Death Ligand 1 and Radiologic Invasiveness in Pathologic Stage I Lung Adenocarcinoma

AU - Toyokawa, Gouji

AU - Takada, Kazuki

AU - Okamoto, Tatsuro

AU - Kawanami, Satoshi

AU - Kozuma, Yuka

AU - Matsubara, Taichi

AU - Haratake, Naoki

AU - Takamori, Shinkichi

AU - Akamine, Takaki

AU - Katsura, Masakazu

AU - Yamada, Yuichi

AU - Shoji, Fumihiro

AU - Baba, Shingo

AU - Kamitani, Takeshi

AU - Oda, Yoshinao

AU - Honda, Hiroshi

AU - Maehara, Yoshihiko

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Background Programmed death ligand 1 (PD-L1) was reported to predict the response of immunotherapy; however, the association between PD-L1 expression and radiologic and pathologic features has yet to be elucidated. Methods In all, 292 patients with resected pathologic stage I adenocarcinoma were analyzed for PD-L1 expression by immunohistochemistry and evaluated to determine the association between PD-L1 expression and the radiologic/pathologic invasiveness. Specifically, the radiologic invasiveness and noninvasiveness were determined based on the consolidation/tumor ratio, with a cutoff value of 0.25 by thin-section computed tomography. Results Among 292 patients, 47 (16.1%) were positive for PD-L1 expression; the remaining 245 patients (83.9%) were negative for PD-L1 expression. Fisher's exact test demonstrated that PD-L1 expression was significantly associated with a higher consolidation/tumor ratio (p = 0.029) and higher maximum standardized uptake value (p = 0.004). The mean values of consolidation/tumor ratio and maximum standardized uptake in patients with and without PD-L1 expression were 0.845 ± 0.052 and 7.241 ± 0.795, and 0.607 ± 0.023 and 3.60 ± 0.364, respectively (p < 0.001 and p < 0.001, respectively). Among 47 adenocarcinomas harboring PD-L1 expression, the frequencies of PD-L1 expression for consolidation/tumor ratios of 0, 0.1 to 0.25, 0.26 to 0.5, and 0.51 or more were 6.4%, 2.1%, 4.3%, and 87.2%, respectively (p = 0.007). Pathologically, PD-L1 was identified exclusively only in more invasive subtypes, not in less invasive ones, such as atypical adenomatous hyperplasia, adenocarcinoma in situ, minimally invasive adenocarcinoma, and lepidic predominant ones (p < 0.001). Conclusions Expression of PD-L1 was significantly associated with radiologic/pathologic invasive adenocarcinomas. This study provides the first evidence of the radiologic and pathologic invasiveness in resected pathologic stage I adenocarcinoma with PD-L1 expression.

AB - Background Programmed death ligand 1 (PD-L1) was reported to predict the response of immunotherapy; however, the association between PD-L1 expression and radiologic and pathologic features has yet to be elucidated. Methods In all, 292 patients with resected pathologic stage I adenocarcinoma were analyzed for PD-L1 expression by immunohistochemistry and evaluated to determine the association between PD-L1 expression and the radiologic/pathologic invasiveness. Specifically, the radiologic invasiveness and noninvasiveness were determined based on the consolidation/tumor ratio, with a cutoff value of 0.25 by thin-section computed tomography. Results Among 292 patients, 47 (16.1%) were positive for PD-L1 expression; the remaining 245 patients (83.9%) were negative for PD-L1 expression. Fisher's exact test demonstrated that PD-L1 expression was significantly associated with a higher consolidation/tumor ratio (p = 0.029) and higher maximum standardized uptake value (p = 0.004). The mean values of consolidation/tumor ratio and maximum standardized uptake in patients with and without PD-L1 expression were 0.845 ± 0.052 and 7.241 ± 0.795, and 0.607 ± 0.023 and 3.60 ± 0.364, respectively (p < 0.001 and p < 0.001, respectively). Among 47 adenocarcinomas harboring PD-L1 expression, the frequencies of PD-L1 expression for consolidation/tumor ratios of 0, 0.1 to 0.25, 0.26 to 0.5, and 0.51 or more were 6.4%, 2.1%, 4.3%, and 87.2%, respectively (p = 0.007). Pathologically, PD-L1 was identified exclusively only in more invasive subtypes, not in less invasive ones, such as atypical adenomatous hyperplasia, adenocarcinoma in situ, minimally invasive adenocarcinoma, and lepidic predominant ones (p < 0.001). Conclusions Expression of PD-L1 was significantly associated with radiologic/pathologic invasive adenocarcinomas. This study provides the first evidence of the radiologic and pathologic invasiveness in resected pathologic stage I adenocarcinoma with PD-L1 expression.

UR - http://www.scopus.com/inward/record.url?scp=85017174067&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017174067&partnerID=8YFLogxK

U2 - 10.1016/j.athoracsur.2016.12.025

DO - 10.1016/j.athoracsur.2016.12.025

M3 - Article

C2 - 28347537

AN - SCOPUS:85017174067

VL - 103

SP - 1750

EP - 1757

JO - Annals of Thoracic Surgery

JF - Annals of Thoracic Surgery

SN - 0003-4975

IS - 6

ER -